No abstract

and one-third (33.9%) were 'not confident' or 'not at all confident' in managing skin conditions in patients with SOC (Fig. 1c). Lack of exposure to patients with SOC was cited by 60.7% of participants as the biggest challenge to looking after these patients (Fig. 1d), which was not an unexpected finding, as 67.9% of respondents estimated that < 5% of their patients had SOC. Specific conditions that were noted to be difficult to diagnose or manage included (i) inflammatory dermatoses (n = 29) such as atopic dermatitis and lupus, (ii) pigmentary disorders (n = 16) such as melanocytic naevi and vitiligo, and (iii) keloid scarring (n = 4). Suggested solutions to improving knowledge included dedicated study days, online resources, cultural training and dedicated teaching clinics.This study shows that Irish dermatologists have low confidence in diagnosing and managing conditions in people with SOC. This is consistent with a previous study showing that only 56% of Australian dermatologists were confident in diagnosing and 75% confident in managing common dermatoses in patients with SOC. 2 This discrepancy in confidence between skin types is important as patients with more darkly pigmented skin are more likely to have negative outcomes from dermatological disease, including melanoma. 3 It has recently been shown that white skin is over-represented in images of COVID-19associated eruptions. 4 With growing awareness of racial equity in medicine, 5 efforts are being made to increase the availability of clinical images highlighting the appearance of dermatoses in SOC. Resources to improve education in SOC include the Skin Diversity Subcommittee of the British Association of Dermatologists, and the associations Skin Deep (https://dftbskindeep.com/) and Skin of Color Society (https://skinofcolorsociety.org/).In conclusion, Irish dermatologists have low confidence with skin pathology in SOC, and specific training could reduce this disparity.

Background. Hidradenitis suppurativa (HS) is a chronic, relapsing and debilitating inflammatory disease associated with profound morbidity. Aim. In this multicentre study, we investigated the demographic and clinical features of HS, and determined risk factors of disease severity. Methods. In total, 1221 patients diagnosed with HS from 29 centres were enrolled, and the medical records of each patient were reviewed. Results. The mean age of disease onset was 26.2 AE 10.4 years, and almost 70% (n = 849) of patients were current or former smokers. Mean disease duration was 8.9 AE 8.4 years with a delay in diagnosis of 5.8 AE 3.91 years. Just over a fifth (21%; n = 256) of patients had a family history of HS. The axillary, genital and neck

Background Chronic spontaneous urticaria (CSU) is a disease that can affect the patient's quality of life (QoL), sexual functions, and mood. Objective We planned a retrospective study to investigate the effects of omalizumab use in CSU patients on sexual function. We also aimed to evaluate the sexual function, quality of life (QoL), and mood of CSU patients compared to the control group consisting of idiopathic pruritus patients. Methods A review of patients’ records with CSU attending the dermatology outpatient clinic from January 2020 to June 2020 was done. Urticaria activation score (UAS7), Beck depression inventory (BDI), Dermatology life quality index (DLQI), female sexual function index (FSFI) to female participants, and the international index of erectile function (IIEF) to male participants were used to assess the impact of the disease on patients’ life. The obtained data were analyzed by using SPSS software. Results Each one of the mean UAS, BDI, and DLQI score values decreased significantly in weeks in omalizumab group patients. IIEF score in male patients and FSFI score in female patients also increased in weeks in omalizumab group patients. Conclusions Omalizumab can play an effective role in enhancing the sexual function of CSU patients in addition to improving their DLQI.

Acne and rosacea are two well‐known chronic skin diseases in dermatology. There are many known therapeutic options of both diseases, but new treatment agents and therapeutic advances come to the agenda day by day. We would like to summarize new treatment advances for acne and rosacea diseases.